Author:
Callander Natalie,Markovina Stephanie,Eickhoff Jens,Hutson Paul,Campbell Toby,Hematti Peiman,Go Ronald,Hegeman Robert,Longo Walter,Williams Eliot,Asimakopoulos Fotis,Miyamoto Shigeki
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference39 articles.
1. Kyle R, Rajkumar SV (2006) Multiple Myeloma. Blood 111:2962–2972
2. Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3534–3540
3. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617
4. Jagannath S, Barlogie B, Berenson J (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165–172
5. Berenson JR, Yang HH, Sadler K et al (2006) A phase 1/2 trial assessing bortezomib and melphalan combination therapy for relapsed or refractory multiple myeloma. J Clin Oncol 24:937–944
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献